An Open-label, Phase 1 Study to Assess Safety, Tolerability, Dosimetry, Pharmacokinetics and Imaging Properties of 89Zr-olaratumab (89Zr-TLX300-CDx) in Participants With Soft Tissue Sarcoma.
Latest Information Update: 07 Apr 2025
At a glance
- Drugs Radionuclide olaratumab conjugate (Primary)
- Indications Soft tissue sarcoma
- Focus Adverse reactions; First in man; Pharmacokinetics; Proof of concept
- Acronyms ZOLAR
- Sponsors Telix Pharmaceuticals
Most Recent Events
- 01 Apr 2025 According to the Telix Pharmaceuticals Media Release, company announces that a first patient has been dosed in this trial.
- 19 Dec 2024 Planned End Date changed from 1 Jun 2026 to 1 Aug 2026.
- 19 Dec 2024 Planned primary completion date changed from 1 Dec 2025 to 1 Mar 2026.